Incentive Program

The EGM in Chordate Medical Holding AB (Publ.) on October 5th, 2021, agreed to establish a long-term incentive program through a resolution on a directed issue of a maximum of 5,500,000 warrants, entailing an increase in the share capital upon full exercise by a maximum of SEK 1,375,000, in accordance with the Board’s proposal.

The issue is carried out with the deviation from the shareholders’ preferential rights, in accordance with what has been previously communicated, with the purposes that through the introduction of an incentive program, current and future employees and consultants in the Company will be able to become long-term shareholders and work for, and take part of, a positive value development of the share in the Company during the period covered by the proposed program, and that the Company will be able to retain and recruit competent and committed staff.

The Holder shall have the right to subscribe for a new Share for each Option Right during the period from 1 November 2025 to 30 November 2025, or even the earlier or later day that may follow from § 8 of the full terms. The subscription price per Share shall correspond to 150 percent of the volume-weighted average price according to Nordic SME’s official price list for the Share during the trading days that fall during the period from 22 September 2021 to 5 October 2021.

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact